[Congressional Bills 103th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2079 Introduced in House (IH)]

103d CONGRESS
  1st Session
                                H. R. 2079

To amend the Federal Food, Drug, and Cosmetic Act and the Public Health 
      Service Act with respect to myelogram-related arachnoiditis.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 11, 1993

Mr. Traficant introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To amend the Federal Food, Drug, and Cosmetic Act and the Public Health 
      Service Act with respect to myelogram-related arachnoiditis.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Myelogram-Related Arachnoiditis 
Amendments of 1993''.

SEC. 2. ADULTERATED MYELOGRAMS.

    Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
351) is amended by adding at the end the following:
    ``(j) If it is a myelogram involving the use of Pantopaque, 
Amipaque, Omipacque, or Isovue.''.

SEC. 3. MYELOGRAM-RELATED ARACHNOIDITIS; ACTIVITIES OF NATIONAL 
              INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE.

    Subpart 10 of part C of title IV of the Public Health Service Act 
(42 U.S.C. 285j et seq.) is amended by adding at the end the following 
section:

                   ``myelogram-related arachnoiditis

    ``Sec. 459A. With respect to individuals who have undergone the 
diagnostic procedure known as a myelogram and who have subsequently 
developed cases of arachnoiditis, the Director of the Institute shall--
            ``(1) conduct or support a study to develop an estimate of 
        the number of such individuals in the United States;
            ``(2) conduct or support research to determine the extent 
        to which such cases are associated with the use of such 
        procedure; and
            ``(3) conduct or support research on treatments for such 
        cases in such individuals, including treatments to manage 
        pain.''.

                                 <all>